NCT06129617 (ADVOMITTENT) is a NA clinical trial of Hemodialysis in Liver Cirrhosis, sponsored by University Medical Center Mainz.

Who is sponsoring NCT06129617?

NCT06129617 is sponsored by University Medical Center Mainz.

What drugs are being tested in NCT06129617?

Interventions in NCT06129617: Hemodialysis, ADVOS.

What condition does NCT06129617 study?

NCT06129617 studies Liver Cirrhosis, Kidney Failure, Acute, Kidney Replacement, Multi Organ Failure.

Is NCT06129617 still recruiting?

NCT06129617 is currently recruiting now. Last updated 13 November 2023.

Last reviewed 2023-11-13 · How we verify

NCT06129617: ADVOMITTENT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intermittent ADVOS vs. Hemodialysis in Non-intensive Care Patients With Liver Dysfunction

Recruiting now NA Last updated 13 November 2023

What this trial tests

NA trial testing Hemodialysis in Liver Cirrhosis in 14 participants. Currently enrolling.

Timeline

1 June 2023

Primary endpoint
1 June 2025

1 June 2026

Quick facts

Lead sponsor	University Medical Center Mainz
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	1 June 2023
Primary completion	1 June 2025
Estimated completion	1 June 2026
Sites	1 location across Germany

Drugs / interventions tested

Hemodialysis
ADVOS

Conditions studied

Liver Cirrhosis — all drugs for Liver Cirrhosis →
Kidney Failure, Acute — all drugs for Kidney Failure, Acute →
Kidney Replacement — all drugs for Kidney Replacement →
Multi Organ Failure — all drugs for Multi Organ Failure →

Sponsor

University Medical Center Mainz

Who can join

18 and older, any sex, with Liver Cirrhosis or Kidney Failure, Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the planned randomized controlled prospective pilot study, we aim to evaluate ADVOS compared with conventional hemodialysis regarding the elimination of protein-bound toxins in patients with therapy-refractory hepatorenal syndrome. The study will be performed in a regular non-ICU ward with a large experience in the use of the ADVOS therapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Advanced Organ Support (ADVOS) hemodialysis system fulfills its intended purpose: Analysis of data from 282 patients from the Registry on Extracorporeal Multiple Organ Support (EMOS).
Fuhrmann V, Tyczynski B, Perez Ruiz de Garibay A, Bingold TM, et al · · 2025 · PMID 41343462 · DOI 10.1371/journal.pone.0318917

Verify or expand the search:

Other trials of Hemodialysis

Trials testing the same drug.

NCT07054827 — Effect of Intradialytic Resistance Versus Aerobic Exercise on Cardiovascular System in Patients on Regular Hemodialysis · NA · not yet recruiting
NCT06141798 — Twice vs Thrice Weekly Incident Hemodialysis in Elderly Patients · NA · recruiting
NCT04705701 — Comparing Post Cardiac Surgery Outcomes in ESRD Patient's With Early Dialysis Versus Standard Care · NA · withdrawn
NCT04527328 — A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment · NA · completed
NCT04095039 — HiLo: Pragmatic Trial of Higher vs Lower Serum Phosphate Targets in Patients Undergoing Hemodialysis · NA · terminated

Other recruiting trials for Liver Cirrhosis

Currently open trials in the same condition.

NCT07439939 — Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Place · recruiting
NCT07325526 — A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- · Phase 2 · recruiting
NCT07418008 — The Liver Cirrhosis Cognitive Decline Scale (LiCCoS) · recruiting
NCT07201649 — Roles of Hepatic Insufficiency, Hepatic Fibrosis, and Inorganic Pyrophosphate in the Progression of Arterial Calcificati · NA · recruiting
NCT07252102 — Effect of HFNC on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients · NA · recruiting

Other University Medical Center Mainz trials

Trials by the same sponsor.

NCT05877768 — Evaluation of PCD-CT Based Image Parameters in the Assessment and Quantification of Coronary Artery Disease · not yet recruiting
NCT05841498 — Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome · NA · completed
NCT04306458 — RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial). · NA · recruiting
NCT03942718 — Systemic Lupus Erythematosus Exercise Program · NA · completed
NCT06508879 — Does Occlusive Hydrocolloid Silver-containing Wound Dressing After Sternotomy Reduce Surgical Side Infection After Cardi · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06129617 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Medical Center Mainz
Last refreshed: 13 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06129617.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing